http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20170086489-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_36089addd8e49e968b4c7e13c517dd1c |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0075 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1617 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1623 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-167 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-167 |
| filingDate | 2015-10-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_07c5afc3e3aeede2bbb5cd54ebf15ea9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_daa851e7178d76f43da9a1500a5f6fc7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c6333bab362a8f38d47b3a5c2c991753 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_67e793453338071fb82e4a7aa7d2607e |
| publicationDate | 2017-07-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20170086489-A |
| titleOfInvention | Pharmaceutical composition containing budesonide and formoterol |
| abstract | The present invention relates to an inhalation preparation of a drug in the form of a dry powder for inhalation administration, which is suitable for the treatment of obstructive airways diseases such as asthma and chronic obstructive pulmonary disease (COPD). In particular, the present invention relates to a pharmaceutical composition comprising, as a first powder, budesonide or a pharmaceutically acceptable salt thereof in an amount greater than 5% by weight of the first powder, leucine in an amount of 5 to 70% A first powder comprising lactose in an amount of 20 to 90% by weight of the first powder; Wherein the second powder comprises formoterol or a pharmaceutically acceptable salt thereof in an amount greater than 1% by weight of the second powder, leucine in an amount of 5 to 70% by weight of the second powder, 20 A second powder comprising lactose in an amount of about 90% by weight; And a third powder comprising a mixture of a first lactose having an X50 of 35 to 75 占 퐉 and a second lactose having an X50 of 1.5 to 10 占 퐉, wherein the content of the first and second lactose in the mixture is 85% to 96% % And 4% to 15% of the total weight of the composition. The composition has a fine particle fraction (FPF) of more than 60% and a delivery fraction (DF) of more than 80%. |
| priorityDate | 2014-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 66.